Dermatomyositis (DM) is an autoimmune disease that affects skeletal muscle and skin, sometimes with heterogeneous systemic manifestations. It is one of the subgroups of the broader diagnoses of ...

New research from Tokyo, Japan could help clarify the role of proinflammatory mediators in the pathogenesis of chronic inflammatory myopathies, such as polymyositis and dermatomyositis.

"These limitations underscore the urgent need to develop more specific and effective therapeutic strategies tailored to the unique pathophysiology of dermatomyositis," noted Farida Benhadou ...

"The FDA's IND approval for our Phase II trial in Dermatomyositis is an exciting milestone,” said Mr ... where the alternative complement pathway (AP) is a key driver of pathogenesis. In DM, the ...

Since patients with refractory Dermatomyositis (DM ... interacts with various mediators and cytokines involved in the pathogenesis of inflammatory and autoimmune diseases, including the interferon ...

Dermatomyositis (DM ... where the alternative complement pathway (AP) is a key driver of pathogenesis. In DM, the dysregulation of AP is recognized as a critical factor in the disease's ...